Fig. 1

Abnormal expression of KDM4B is an indicator of a poor prognosis in glioma patients. A The expression of KDM4B in GBM and many other tumor types was determined using the GEPIA (http://gepia.cancer-pku.cn/index.html) databases. B Expression of KDM4B in normal human brain cells versus gliomas and GBM using the Brainbase (https://ngdc.cncb.ac.cn/brainbase/) date. C The CNV levels of KDM4B were detected in different grades of gliomas. G2 = Grade II Glioma, G3 = Grade III Glioma, G4 = GBM, CNV = Copy Number Variation. D CNV levels of KDM4B were detected between IDH-mutant and IDH-wild-type statuses. E CNV levels of KDM4B were detected between the 1p/19q codel and 1p/19q non-codel statuses. F Comparison of survival probability in glioma patients among normal, gain and loss of DNA in the CNV regions of KDM4B. G, H High KDM4B expression is associated with reduced overall survival in glioma patients. Patient data analyses were conducted online (R2 Genomics Analysis and Visualization Platform), and the resulting figures and log-rank test p values were downloaded. I The expression levels of KDM4B in various cell lines including the glial cell line (SVGP12), as well as the LGG cell lines (SW1088, SW1783), and the GBM cell lines (U118, U251, A172, LN229, and U87-MG). *p < 0.05; ***p < 0.001